Howard A. “Skip” Burris, MD
Ongoing clinical trials are exploring novel approaches in triple-negative breast cancer (TNBC), such as PARP inhibition and immunotherapy.
Early promise has already been observed, as phase Ib/II findings found that a combination of eribulin (Halaven) and pembrolizumab (Keytruda) was associated with an objective response rate (ORR) of 41.2% for untreated patients with metastatic TNBC.1
... to read the full story